WARSAW — Zimmer Biomet Holdings Inc. announced it has successfully completed its offer to purchase all outstanding shares of the common stock of LDR Holding Corporation for $37 per share, net to the seller in cash, without interest, less any deductions or withholding of taxes required by applicable law.

The tender offer expired at midnight, New York City time, July 13. As of the expiration of the tender offer, 24,278,729 shares of LDR common stock had been validly tendered and not properly withdrawn (excluding shares of LDR common stock tendered pursuant to guaranteed delivery procedures that have not yet been “received,” as such term is defined in section 251(h) of the General Corporation Law of the State of Delaware), representing approximately 82.7 percent of the outstanding shares of LDR common stock.

As of the expiration of the tender offer, notices of guaranteed delivery had been delivered for 1,826,189 shares of LDR common stock, representing approximately 6.2 percent of the outstanding shares of LDR common stock. All conditions to the tender offer have been satisfied and Zimmer Biomet has accepted for payment and will promptly pay the depositary for all validly tendered shares that have not been properly withdrawn.

David Dvorak, President and CEO of Zimmer Biomet, commented, “We are excited to officially welcome LDR to the Zimmer Biomet family. Together with LDR, Zimmer Biomet will be a leader in the $10 billion global spine market and well-positioned in the fast growing cervical disc replacement segment. Importantly, this combination is consistent with our goal of driving meaningful growth across all musculoskeletal markets with innovative products, technologies and services that enhance patient outcomes.”

Zimmer Biomet expects to complete the acquisition of LDR later today through a merger without a vote or meeting of LDR’s stockholders pursuant to Section 251(h) of the General Corporation Law of the State of Delaware. All remaining shares of LDR common stock not purchased in the tender offer (other than treasury shares held by LDR, any shares owned by Zimmer Biomet, LH Merger Sub Inc. or any direct or indirect subsidiary of Zimmer Biomet or LDR and any shares held by any LDR stockholder who has properly demanded appraisal rights) will be converted into the right to receive the same per share consideration of $37 in cash, without interest, less any deductions or withholding of taxes required by applicable law, that will be paid in the tender offer.

Upon completion of the merger, LDR will become an indirect wholly owned subsidiary of Zimmer Biomet. LDR common stock will no longer be listed on the NASDAQ Global Select Market.